Rapamycin (Sirolimus)

Pfizer辉瑞授权 目录号:S1039 别名: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。

规格 价格 库存 购买数量  
RMB 2501.99 现货
RMB 580.39 现货
RMB 2216.87 现货
RMB 5501.68 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献66篇:

客户使用该产品的13个实验数据:

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

产品安全说明书

mTOR抑制剂选择性比较

生物活性

产品描述 Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。
靶点
mTOR [1]
(HEK293 cells)
~0.1 nM
体外研究

Rapamycin作用于HEK293细胞,抑制内源性mTOR活性,IC50为~0.1 nM,而iRap和AP21967 作用时,IC50分别为~5 nM 和~10 nM。[1] Rapamycin处理酿酒酵母,诱导细胞周期停在G1/S期,且抑制翻译。[2] Rapamycin显著抑制T98G和U87-MG细胞活力,这种作用具有剂量依赖性,IC50分别为2 nM和 1 μM, 而对U373-MG细胞没有作用活性,IC50>25 μM。Rapamycin(100 nM) 作用于对Rapamycin敏感的U87-MG和T98G细胞,通过抑制mTOR功能,而诱导细胞周期停在G1期,也诱导自噬而不是凋亡。[6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NIXCemhEgXSxdH;4bYMhSXO|YYm= M4fVbFExKG6P Mnn5O|IhcA>? NYO5ZVQyTE2VTx?= NVHY[mxlWG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NGfSVJAzPDlyMEi3Ny=>
HT-29 NFrNfIlEgXSxdH;4bYMhSXO|YYm= NFO4XJoyOCCwTR?= NY\2PXd{PzJiaB?= MlzzSG1UVw>? MnnMVI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7 MYmyOFkxODh5Mx?=
HT-29 NE\wUGNEgXSxdH;4bYMhSXO|YYm= NUWwSHRFOTBibl2= NH21NWY4OiCq M1LTbmROW09? NVPScVR3WG:2ZX70bYF1\XNiNT3mcJVwem:3cnHjbYwucW6mdXPl[EBkgXSxdH;4bYNqfHl? NUW2TldmOjR7MEC4O|M>
PC3 NUPRPFRGU2mwYYPlJGF{e2G7 M1PvRVExOCCwTR?= NXXGXll3OSCq NInSNZdFVVOR M1;5WnBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kA9OTBibl2u NYS0[|MzOjF7N{i2PFM>
PC3 MYXLbY5ie2ViQYPzZZk> MnHFNVAxKG6P MWmxJIg> NET2Nm9FVVOR NWDvfHNETG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= MVyyNVk4QDZ6Mx?=
PC3 NFzSVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknxNU42KM7:TR?= MWexJIg> M1TyWWROW09? M13INWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?= NVX3eoJROjF7N{i2PFM>
HEK293 MUjGeY5kfGmxbjDBd5NigQ>? MWmxNFAhdk1? M1z3UVghcA>? NG\PNnpFVVOR M2XscWlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= M13sN|IyPTN7M{Cx
BT-20 MU\LbY5ie2ViQYPzZZk> MUGyNEDPxE1? NIOxcYNFVVOR NF7SWGRFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= NInTSHAzOTN3M{W1NS=>
U937 MWfBcpRq[mGldHXybYFtKEG|c3H5 M2raTFUxKM7:TR?= MnvUOFghcA>? M1z0dmROW09? NHPZOJdKdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N|ch[2WubIO= M4rWNFIyOTR{MUC2
U937 NF3jWpBCdnSrYnHjeIVzcWGuIFHzd4F6 M3Twb|UxKM7:TR?= MXe0PEBp NVSxOot4TE2VTx?= Ml3sSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? NGrRXHAzOTF2MkGwOi=>
U937 Ml3FRY51cWKjY4TldolidCCDc4PhfS=> MXe1NEDPxE1? NXKwenFJPDhiaB?= NHq2cYRFVVOR MVLEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=> M{DkOVIyOTR{MUC2
MCF-7 MoTaRZV1d3CqYXf5JGF{e2G7 MlrwN|Ahdk1? NVnHXZN3PCCq Mn:5SG1UVw>? M2f1PWlv\HWlZYOgZZV1d3CqYXf5 M1nMV|IxODJ6MUO0
U87MG MmLJT4lv[XOnIFHzd4F6 NVvVZW1rOSEQvF2= NFrRRZA3KGh? MXTEUXNQ NG\qR2pRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbh?= Mo\DNVk5PDh2MES=
U87MG M3:yVGtqdmG|ZTDBd5NigQ>? NV7K[VlnOSEQvF2= NXHzcppJPiCq M1:5XGROW09? M1vWVHBwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;u MoHENVk5PDh2MES=
U87MG MmTaT4lv[XOnIFHzd4F6 MX6xJO69VQ>? MXy2JIg> MVvEUXNQ MXLEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MmXHNVk5PDh2MES=
U87MG MorNT4lv[XOnIFHzd4F6 MkLPNUDPxE1? MY[2JIg> NWL1cYRxTE2VTx?= MUnEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> NWDhdmRJOTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rheb NV;ne|hMSXW2b4DoZYd6KEG|c3H5 M3nrdVAvOiEQvF2= NImzR|AzPCCq Mm\OSG1UVw>? M4jBdWlv\HWlZYOgZZV1d3CqYXf5 M2D6SFE5OzlzOUS5
COS7 cells expressing EGFP-LC3 NFqxdopCfXSxcHjh[5khSXO|YYm= MWiwMlIh|ryP NWPCSHZKOjRiaB?= MofqSG1UVw>? MWXJcoR2[2W|IHH1eI9xcGGpeR?= M13ZblE5OzlzOUS5
H4 M3;jbGZ2dmO2aX;uJGF{e2G7 NECwNosxNjJizszN NVPzTXI2OjRiaB?= M3[0eWROW09? MljJTY5kemWjc3XzJJRp\SC{YYTpc{Bw\iCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNkB1dyCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNUBqdiCqdX3hckBJPCClZXzsdy=> MmrXNVgxOjR3OES=
HeLa MojzSpVv[3Srb36gRZN{[Xl? Mn\3NVAxKG6P NIHLSIc{PiCq NWe2c5BZTE2VTx?= MVzJcoR2[2W|IF\SRkBMOjB7NWCsJHQzODl6TDygW|IyODGIIH31eIFvfC23YnnxeYl1cW6FIHnueIVz[WO2aX;u M2nZelE4PTZ|M{i1
HeLa NVzjPHhvTnWwY4Tpc44hSXO|YYm= NYPEWnZxOTByIH7N M1r5U|M3KGh? MXzEUXNQ NFPGOo5KdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25? MXmxO|U3OzN6NR?=
HeLa Mn\uSpVv[3Srb36gRZN{[Xl? MUWxNFAhdk1? NW[wdFdTOzZiaB?= NYXySYFlTE2VTx?= NVjz[4tjUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v MlmyNVc2PjN|OEW=
SYF M{XTW2Z2dmO2aX;uJGF{e2G7 MWGxNFAhdk1? MlnHNlQhcA>? NFnIO|dFVVOR NXrIZWJ{UW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v M1HsTlE4PTZ|M{i1
SYF MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmCyNVAxKG6P M4q2OFI1KGh? MljkSG1UVw>? M1nzSWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDTXWYh[2WubIO= NVLZNFBzOTd3NkOzPFU>
HEK293T NH7WVItCdnSrdnnyZYwhSXO|YYm= MlG2NUBvVQ>? MkjoOEBl M2PGS2ROW09? MV7JcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?= MkPUNVc1QDV3MEG=
HEK293T NUXQNXB{SW62aY\pdoFtKEG|c3H5 NUjkTFNXOSCwTR?= NX;5WHZVPCCm MWnEUXNQ Mn;vTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2= NIOyR|cyPzR6NUWwNS=>
PBMC MofZSpVv[3Srb36gRZN{[Xl? MWqxJI5O MUmxOEBl NUfyOXNDTE2VTx?= NYDsVGJ3WmWmdXPld{BES1J3IHTlcpNqfHl? M4rpU|E4PDh3NUCx
PBMC MnLmSpVv[3Srb36gRZN{[Xl? MlfMNUBvVQ>? NXjrOGF3OTRiZB?= MmXvSG1UVw>? NVHRO3JlTG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? MmSxNVc1QDV3MEG=
HEK293 cells Mkm3T4lv[XOnIFHzd4F6 MoLLOVAhdk1? NHvKdZM1PSCvaX6= NYjLU5FyTE2VTx?= M2rJPWlvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1? NHfYWoEyPzN3MEm1Ny=>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MnjESpVv[3Srb36gRZN{[Xl? M13qelExOCCwTR?= NEPVb2c1KGh? NEfCU3pFVVOR NXfYSlZtUW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? MYOxO|EzQDJ4Mh?=
Human mixed lymphocyte NEPNTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fyUlUhdk1? MoX6SG1UVw>? NV61ZXRTUUN3ME2xMlYhdk1w NXvtS3FLOTZzOEW4OlU>
Lewis rat lymph node cells NXzXcJFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDqUmw2KM7:TR?= M{KycGROW09? MonOTWM2OD1{Lk[g{txO MYqxOlE5PTh4NR?=
cells from the thymus of normal BALB/c mice NYPSepUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPoeXhFOTBibl2= M3TzVVczKGh? NEjrT21FVVOR MoDtTY5pcWKrdIOgcJlueGixcILvcIln\XKjdHnvckApVEGIKTD3bZRpKEmFNUCgc4YhOyCwTR?= NUDUS4xzOTByMkG5OFg>
MRK-nu-1 M4PQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwOES1JJBO MnfRV2FPT0WU
OCUB-M MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzXTWM2OD13LkK0JJBO MUXTRW5ITVJ?
SF539 NX7zSFhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTFzLk[gdG0> NHrwR5hUSU6JRWK=
ES4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[wTVBFUUN3ME2yNU42KHCP NXfae5E5W0GQR1XS
RL95-2 M2P1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvnVVNKSzVyPUGwO{BxVQ>? M3vVNXNCVkeHUh?=
LC-2-ad MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm3TGRiUUN3ME20NlMheE1? NH;QcWlUSU6JRWK=
Daudi MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjvbXlOUUN3ME20N|QheE1? MnvUV2FPT0WU
NTERA-S-cl-D1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjwTWM2OD12NEOgdG0> MYPTRW5ITVJ?
OS-RC-2 Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTZ3MjDwUS=> NIL1Z49USU6JRWK=
VA-ES-BJ NWPvWmY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3HTWM2OD15MkOgdG0> NH[5[nZUSU6JRWK=
GR-ST NXXmOpZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO5TWM2OD16NE[gdG0> NUDKSVRSW0GQR1XS
SW872 NV2xSJc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTh2NjDwUS=> MkjPV2FPT0WU
NOS-1 M1ztUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPTPG92UUN3ME24O|EheE1? NWDjWmtCW0GQR1XS
MC116 M1XZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rvemlEPTB;OUi1JJBO MmH6V2FPT0WU
NCI-H1355 MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzWbWYxUUN3ME2xMlAyKG6P NIKxSXlUSU6JRWK=
RPMI-8226 M3frdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7DTWM2OD1zLkG5JI5O M33SXXNCVkeHUh?=
TE-15 NEDnenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfhfnk2UUN3ME2xMlM3KG6P NVPvWXBYW0GQR1XS
Ramos-2G6-4C10 NUnlZYdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHGbFhKSzVyPUGuOFYhdk1? MYrTRW5ITVJ?
KU812 NF\HV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnuXoFKSzVyPUKuNFEhdk1? MnzVV2FPT0WU
EW-1 Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTMTWM2OD1{LkG3JI5O NGXaU2ZUSU6JRWK=
KS-1 MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXOUmlXUUN3ME2yMlQ2KG6P NVnyWXZwW0GQR1XS
SK-LMS-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr3TWM2OD1{LkS5JI5O NHfpZVhUSU6JRWK=
TGBC1TKB NILiZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJwNkmgcm0> Ml7YV2FPT0WU
TE-6 NHPWTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJwN{egcm0> NFzOR4hUSU6JRWK=
ETK-1 MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzNWHpKSzVyPUKuPFIhdk1? M1LBOnNCVkeHUh?=
BE-13 NGTG[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDRTWM2OD1{Lkm5JI5O NYrJOYhuW0GQR1XS
A3-KAW MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHqTWM2OD1{Lkm5JI5O MYDTRW5ITVJ?
TE-10 NETrO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXixWGlwUUN3ME2zMlMhdk1? M{nYN3NCVkeHUh?=
DOHH-2 NIjSOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jKSGlEPTB;Mz6zOUBvVQ>? MVHTRW5ITVJ?
ES6 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHxTWM2OD1|LkSzJI5O M4OyTXNCVkeHUh?=
OPM-2 MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7xXW5zUUN3ME20MlE2KG6P MWHTRW5ITVJ?
SH-4 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PjcWlEPTB;ND6zOEBvVQ>? NEjJUoFUSU6JRWK=
NB13 NWPWbYxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjKWmRnUUN3ME20MlM3KG6P NIf4bGNUSU6JRWK=
HUTU-80 M3O2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jGR2lEPTB;ND60NkBvVQ>? NVLFVJVzW0GQR1XS
CCRF-CEM NWjCVJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf2dYdKSzVyPUSuPVQhdk1? MkHYV2FPT0WU
TGBC24TKB MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\iZ2lEPTB;NT61NUBvVQ>? MkXKV2FPT0WU
697 NWjyO4w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XvS2lEPTB;Nj6yPEBvVQ>? MmPPV2FPT0WU
J-RT3-T3-5 NFzEXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjyeJVKSzVyPU[uOFYhdk1? Ml2wV2FPT0WU
KALS-1 NGTQRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfuOW9KSzVyPU[uOVYhdk1? Ml7PV2FPT0WU
no-10 NEizNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHIU3hKSzVyPUeuNlkhdk1? NGD0N3BUSU6JRWK=
SK-NEP-1 MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HQUWlEPTB;OD63PUBvVQ>? NVPMUW1OW0GQR1XS
L-540 NH7pNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnXTWM2OD1zMD60NkBvVQ>? M37ORnNCVkeHUh?=
JiyoyeP-2003 NVLEfmEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHOTWM2OD1zMD65OEBvVQ>? MUjTRW5ITVJ?
HH M1jIZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrZ[5FRUUN3ME2xNU4{QSCwTR?= NFnlV4RUSU6JRWK=
SR M3faR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKyPYNKSzVyPUGxMlQ2KG6P MojHV2FPT0WU
QIMR-WIL M1\KcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGra[|ZKSzVyPUGxMlg2KG6P NYruRWg5W0GQR1XS
A4-Fuk MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHnTWM2OD1zMz6xNkBvVQ>? NXfEWW83W0GQR1XS
CESS MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF|LkGzJI5O NITLUJNUSU6JRWK=
KE-37 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTF4LkC3JI5O Mo\CV2FPT0WU
SK-UT-1 MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[2fmlEPTB;MU[uPFEhdk1? NInZVJlUSU6JRWK=
SIG-M5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPyTWM2OD1zNz6yOUBvVQ>? MUHTRW5ITVJ?
HT NV7IUZJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rGbWlEPTB;MUeuOkBvVQ>? NFnmeYdUSU6JRWK=
DEL MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF5Lkm5JI5O Mn;XV2FPT0WU
SK-PN-DW MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfnTWM2OD1{MD6yN{BvVQ>? M1vuW3NCVkeHUh?=
RPMI-8402 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJzLke3JI5O NVrkU4tPW0GQR1XS
RPMI-6666 NXi4Tm9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fBcmlEPTB;MkSuOFIhdk1? NY[5XVhFW0GQR1XS
NCI-H720 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:2TWM2OD1{NT60NUBvVQ>? MlfaV2FPT0WU
EW-16 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJ4Lki3JI5O NEG0c4ZUSU6JRWK=
BL-70 MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFixb4dKSzVyPUK4MlM5KG6P MkHjV2FPT0WU
SF126 NWHhXZllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XiOWlEPTB;M{CuN|ghdk1? M2PRXnNCVkeHUh?=
BC-1 NXPHeYtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHUVY1KSzVyPUOxMlI3KG6P Mo\vV2FPT0WU
MHH-PREB-1 MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTN{LkS0JI5O MWDTRW5ITVJ?
A101D NIrRclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELqWZlKSzVyPUOyMlYzKG6P M2nzd3NCVkeHUh?=
NMC-G1 NX72ZnZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTN|Lk[3JI5O MWDTRW5ITVJ?
LB1047-RCC NWfESmE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPJOGpiUUN3ME2zOE43QSCwTR?= NYXIVXNRW0GQR1XS
EM-2 NX7Y[JhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTtTWM2OD1|OD61N{BvVQ>? MWrTRW5ITVJ?
COLO-684 MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrtZmxKSzVyPUO5Mlghdk1? Mn\4V2FPT0WU
Becker NGnEZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYeyTFR[UUN3ME20NU4xPSCwTR?= MnrxV2FPT0WU
BL-41 M2fXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLyPJR3UUN3ME20N{43PiCwTR?= NGrCbWRUSU6JRWK=
MDA-MB-134-VI Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rab2lEPTB;NESuNFIhdk1? NXL4Um5qW0GQR1XS
L-363 NH;xdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\6fnpDUUN3ME20OE44OyCwTR?= MoDmV2FPT0WU
ECC4 M3P5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXWXlBnUUN3ME20OE44QCCwTR?= NUHwW2ZZW0GQR1XS
A388 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETRXGxKSzVyPUS0MlgzKG6P MlXwV2FPT0WU
HEL NY\qWG0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDaPXBnUUN3ME20PU44QSCwTR?= M4jpR3NCVkeHUh?=
RKO MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHG3XItKSzVyPUWwMlI6KG6P Mm\CV2FPT0WU
KINGS-1 Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLiTWM2OD13MT61OUBvVQ>? Ml3yV2FPT0WU
EB-3 M1zJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn1NYdiUUN3ME21Nk43PyCwTR?= NInI[5hUSU6JRWK=
ARH-77 M1zPZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTV{Lkigcm0> NE\McJhUSU6JRWK=
GCIY M2jF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTV|LkS2JI5O M4K5SnNCVkeHUh?=
NCI-H1304 NIjMOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTV5LkKyJI5O M{nnc3NCVkeHUh?=
KARPAS-299 M{exVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\tUGlEPTB;NkGuPFIhdk1? NVPlc4ltW0GQR1XS
IA-LM NEjZW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rNWGlEPTB;NkiuNVMhdk1? NH\GfZNUSU6JRWK=
GI-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTdyLkO5JI5O M1jEN3NCVkeHUh?=
TE-11 NGLKd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTd5LkG3JI5O MkDlV2FPT0WU
LS-411N Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofpTWM2OD15Nz61O{BvVQ>? MXrTRW5ITVJ?
no-11 NIXMVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TFfmlEPTB;OEOuNlQhdk1? MnvHV2FPT0WU
MV-4-11 M1XNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13h[GlEPTB;OEOuO|Mhdk1? M{XBT3NCVkeHUh?=
BV-173 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3PTWM2OD16Mz65O{BvVQ>? MlrDV2FPT0WU
CMK MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT5TWM2OD16ND6xOkBvVQ>? M2f2WXNCVkeHUh?=
LC4-1 M4TmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37GfGlEPTB;OE[uO|Ihdk1? Ml\2V2FPT0WU
COR-L279 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LmTGlEPTB;OEeuNlUhdk1? M122enNCVkeHUh?=
NCI-H209 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjiU49IUUN3ME24O{41OSCwTR?= M4LnS3NCVkeHUh?=
Raji NGLsWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\6TWM2OD16OT63NkBvVQ>? M{Lad3NCVkeHUh?=
LB996-RCC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PNWWlEPTB;OUOuOFMhdk1? NVyyNmx6W0GQR1XS
NCI-H526 NYDxXY9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTl|LkW5JI5O M1X0b3NCVkeHUh?=
KGN M{DLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fXXGlEPTB;OU[uNlkhdk1? MV7TRW5ITVJ?
MOLT-4 NILOXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLkNXNKSzVyPUm2Mlc6KG6P M1:2ZnNCVkeHUh?=
PF-382 NWTrd3ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nrd2lEPTB;OU[uO|khdk1? M2j5NHNCVkeHUh?=
BC-3 M3vj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDVSoM5UUN3ME25PU4yQCCwTR?= M2LJ[XNCVkeHUh?=
KARPAS-422 M{LpXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjxT3JKSzVyPUGwNk4xQSCwTR?= NV\XZ|JtW0GQR1XS
SBC-1 NXfWN2lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFyNz63OUBvVQ>? NF;RVZdUSU6JRWK=
LC-1F NVLjSol2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTWTWM2OD1zMEiuNFUhdk1? M{[0SHNCVkeHUh?=
GB-1 M4XFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoKyTWM2OD1zMEmuNFIhdk1? M{\BSnNCVkeHUh?=
SNB75 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:2[mlEPTB;MUG5MlY6KG6P NEHPWpBUSU6JRWK=
BB65-RCC MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rnR2lEPTB;MUG5Mlk{KG6P NYXLeXpYW0GQR1XS
NCI-N87 NXyz[417T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYKzbVlxUUN3ME2xNlEvQThibl2= MVnTRW5ITVJ?
IST-MEL1 M3PVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv1TWM2OD1zMkKuN|ghdk1? M4\lSHNCVkeHUh?=
HOP-62 NVHrTXJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfsTWM2OD1zMk[uPFkhdk1? MoXKV2FPT0WU
ACN NX:wNnh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvxZ2hKSzVyPUG0Ok44PSCwTR?= NELrRXBUSU6JRWK=
DMS-114 NYHN[mZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\CTWM2OD1zNUCuOlchdk1? MkPwV2FPT0WU
MLMA NX7Wc3BiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;DVGMzUUN3ME2xOVkvQDhibl2= NF:xPGZUSU6JRWK=
HT-144 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnQTWM2OD1zNkWuOFMhdk1? MoXnV2FPT0WU
C2BBe1 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLZOXFKSzVyPUG2O{44PiCwTR?= NVXBblZyW0GQR1XS
L-428 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP3R2dKSzVyPUG3O{44KG6P MmDVV2FPT0WU
DU-4475 NITXb|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;ERpFPUUN3ME2xPFcvPjhibl2= NF23d|FUSU6JRWK=
CP67-MEL NYTESmg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3NXXJKSzVyPUG5PU4{QCCwTR?= MVLTRW5ITVJ?
MEG-01 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\TXGRKSzVyPUKwNU46PiCwTR?= M{npRnNCVkeHUh?=
IST-SL2 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJyOD62N{BvVQ>? MlrnV2FPT0WU
ES8 M4ixVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zj[GlEPTB;MkK1Mlk1KG6P MX\TRW5ITVJ?
COLO-800 NFvINVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LXbGlEPTB;MkO1MlI5KG6P MWjTRW5ITVJ?
MFH-ino M1f3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzlTWM2OD1{M{WuPFQhdk1? NFG2bIJUSU6JRWK=
OVCAR-4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ|Nz6yOEBvVQ>? M2rxNnNCVkeHUh?=
PSN1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJ2Mj63NUBvVQ>? M4rSWXNCVkeHUh?=
EW-12 NF3HUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqxU2FKSzVyPUK0N{4yKG6P M2DrdXNCVkeHUh?=
HCC1599 M2fYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCyTWM2OD1{NkGuOFchdk1? MnLQV2FPT0WU
SJSA-1 NIPpOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJ5MT60OkBvVQ>? NE\FbJdUSU6JRWK=
ST486 NUPoW20yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHuSJFMUUN3ME2yPVYvOTRibl2= NYjMcFdIW0GQR1XS
NOMO-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjj[2dqUUN3ME2zNFAvOjFibl2= NW[2[5Q{W0GQR1XS
MN-60 NFXXUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfFOoN[UUN3ME2zNFUvOzJibl2= NUjG[FEzW0GQR1XS
HCC1187 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDZdpVKSzVyPUOwO{4zPSCwTR?= NUTLTnZpW0GQR1XS
SW982 M4\ZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f3RmlEPTB;M{G0Mlc2KG6P MUXTRW5ITVJ?
LB647-SCLC M3LXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7odZZKSzVyPUOyPE44OSCwTR?= NFLkTWpUSU6JRWK=
HC-1 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC2TWM2OD1|M{WuOUBvVQ>? M1WzO3NCVkeHUh?=
EHEB M3X3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DC[WlEPTB;M{O3MlUzKG6P M3jCd3NCVkeHUh?=
TUR MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTN4Mz65OUBvVQ>? MVfTRW5ITVJ?
LU-139 MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPJ[ppxUUN3ME2zO|gvODJibl2= Mof1V2FPT0WU
NB1 MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3DTWM2OD1|OESuOFUhdk1? MojRV2FPT0WU
BB30-HNC M2HCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fnS2lEPTB;M{i4MlMzKG6P NH7NR5FUSU6JRWK=
HAL-01 NIS3PGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDBSphKSzVyPUO4PU4zPiCwTR?= M{SyT3NCVkeHUh?=
K5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fC[WlEPTB;NEGxMlM4KG6P M1zKNXNCVkeHUh?=
MZ2-MEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz4TWM2OD12MUOuOlQhdk1? NXHMcXNpW0GQR1XS
RXF393 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\oSWlEPTB;NEG2MlQ2KG6P NWHGVZJlW0GQR1XS
NCI-H1648 MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHhWJVqUUN3ME20NVcvPTNibl2= M4W2dHNCVkeHUh?=
TE-12 Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTR|ND6yOkBvVQ>? NVflSVR[W0GQR1XS
EoL-1- Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPJUHdKSzVyPUSzO{46QCCwTR?= M2WwdHNCVkeHUh?=
JAR MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXOWo9yUUN3ME20N|gvPjJibl2= M37qUnNCVkeHUh?=
DSH1 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TVTmlEPTB;NEW4MlkyKG6P NHzmcXRUSU6JRWK=
NCI-H187 MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYCxe281UUN3ME20OlIvQDFibl2= M4\ESnNCVkeHUh?=
HCE-4 M4e5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkflTWM2OD12N{euOlYhdk1? M2TybXNCVkeHUh?=
8-MG-BA M{C0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7Pe4RKSzVyPUW4NU42OiCwTR?= NYr0d|ZtW0GQR1XS
KLE NH7Dc|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{noOGlEPTB;NUi1MlIhdk1? M1L6WXNCVkeHUh?=
KNS-42 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTV6Nj64NUBvVQ>? MXPTRW5ITVJ?
MSTO-211H M4DGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrUTWM2OD14MEmuO|Qhdk1? NW\W[lN6W0GQR1XS
GDM-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPHUmFKSzVyPU[xOE4xQSCwTR?= NXLGcnJYW0GQR1XS
TE-1 M2jJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTZ2Nj6xNkBvVQ>? M4WwSnNCVkeHUh?=
BT-474 NXW2cYt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X6SGlEPTB;NkS3MlA3KG6P NH74PJBUSU6JRWK=
KARPAS-45 NFfjPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLWXGVrUUN3ME22OFcvPiCwTR?= MUHTRW5ITVJ?
MOLT-16 M4i1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i4S2lEPTB;NkS3Mlk{KG6P MWrTRW5ITVJ?
KURAMOCHI NXHSbGtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTZ3Nz61NUBvVQ>? MonrV2FPT0WU
K-562 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7VTWM2OD14NkmuOVEhdk1? M4rUZnNCVkeHUh?=
EKVX MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorqTWM2OD14N{KuO|Ehdk1? MnvIV2FPT0WU
GAK M3nae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjOTWM2OD14N{WuN{BvVQ>? M3njV3NCVkeHUh?=
NCI-SNU-5 NVL0XYdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfF[WZuUUN3ME22PVAvODFibl2= Mm[0V2FPT0WU
NCI-H2126 NFzmeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfqRYdKSzVyPUeyOk45PyCwTR?= MmrNV2FPT0WU
CTV-1 M172Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLBTWM2OD15NESuPUBvVQ>? NFvDR5lUSU6JRWK=
SW962 M4PMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHHVYVKSzVyPUe0PE41PCCwTR?= NX[3eoJ3W0GQR1XS
MONO-MAC-6 M1v6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXBTHVGUUN3ME23OVYvQTNibl2= MlvaV2FPT0WU
NCI-H748 NEezcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTd3OD65PUBvVQ>? MX;TRW5ITVJ?
NCI-H524 M2\ETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTd6MD63N{BvVQ>? Moi4V2FPT0WU
LS-123 NYrVbol5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPRRmJHUUN3ME23PVUvPjlibl2= NGf5eIpUSU6JRWK=
NB7 NEfKSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nxZmlEPTB;OEG0MlE1KG6P NFOzXXJUSU6JRWK=
LS-1034 MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi0ZZhTUUN3ME24NlgvQThibl2= M{DX[3NCVkeHUh?=
TE-5 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\GcmlEPTB;OEizMlU3KG6P NXThcm1EW0GQR1XS
A704 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTMWZNKSzVyPUi5PU4yPSCwTR?= NUnYRXd[W0GQR1XS
TK10 M1rENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULOT|ZJUUN3ME25NVYvODNibl2= NFfXUFlUSU6JRWK=
NCI-H345 NILyfXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIiySYZKSzVyPUm0N{4zOiCwTR?= NIXUZmJUSU6JRWK=
CGTH-W-1 NGnWPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\SSZN4UUN3ME25OFgvOTNibl2= NYSxNJpOW0GQR1XS
NCI-H510A NWLid2dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPtTWM2OD17OEWuNVIhdk1? M4PkdnNCVkeHUh?=
NCI-H1963 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPpTWM2OD1zLkCzNlkzKM7:TR?= NXS0c3dMW0GQR1XS
SCC-3 NFLwTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjLeHZ{UUN3ME2xMlA{PDF2IN88US=> MUDTRW5ITVJ?
EW-11 NF2yPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fOeWlEPTB;MT6wPFc1OyEQvF2= Mk\UV2FPT0WU
CPC-N MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwMEi4JO69VQ>? M3Tm[nNCVkeHUh?=
NCI-H1417 NXzBdG9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFwMUKyOkDPxE1? NX3YT|U6W0GQR1XS
DG-75 M1Lsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7YTWM2OD1zLkG2Nlg2KM7:TR?= MXXTRW5ITVJ?
HD-MY-Z MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn2fWNKSzVyPUGuNVY1OTZizszN MnPoV2FPT0WU
ATN-1 NXXmO29vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H3cGlEPTB;MT6yOlIxQSEQvF2= NYfRSlR2W0GQR1XS
KM-H2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj4[VFuUUN3ME2xMlI3PDB6IN88US=> MnLDV2FPT0WU
NCI-H2081 MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwMk[2N|ch|ryP MXfTRW5ITVJ?
HL-60 M2\KWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfQeIdKSzVyPUGuNlY6PTlizszN MXrTRW5ITVJ?
DB MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jTSWlEPTB;MT6yO|I1OiEQvF2= NITqOJFUSU6JRWK=
NCI-H1522 M1rTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[0cmlEPTB;MT6yPFg5PyEQvF2= M1jWPXNCVkeHUh?=
AM-38 NWTiZWtST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES4PWhKSzVyPUGuN|A4OiEQvF2= M4LuTnNCVkeHUh?=
NCI-H446 MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[z[WlEPTB;MT6zNlEzOSEQvF2= MYrTRW5ITVJ?
SU-DHL-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwM{K4NFEh|ryP NUTU[Ik2W0GQR1XS
NH-12 M3f2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmmyTWM2OD1zLkO2N|c1KM7:TR?= MVXTRW5ITVJ?
DMS-79 NVS2d21bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrjTWM2OD1zLkO2PFY3KM7:TR?= M3n5dXNCVkeHUh?=
NCI-H716 NEnXO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfaNXM{UUN3ME2xMlM5QTh4IN88US=> NYjCdXY{W0GQR1XS
ML-2 M3zKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1KxT2lEPTB;MT60NVUzQSEQvF2= NGjmTndUSU6JRWK=
NB10 NIDmN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rLXmlEPTB;MT60OlY{OiEQvF2= NUDYdZc5W0GQR1XS
ONS-76 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C0dGlEPTB;MT61N|U3QSEQvF2= M3;DbHNCVkeHUh?=
LOUCY Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwNUS2OVch|ryP M4THOHNCVkeHUh?=
SCLC-21H M3u4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwNUi1PFIh|ryP NVTLWphHW0GQR1XS
TGW M2\Pb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwNkO5O|Uh|ryP NWrYZYxZW0GQR1XS
LXF-289 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ThUWlEPTB;MT63N|I3QCEQvF2= NFnjTlhUSU6JRWK=
BB49-HNC M{L3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7xfIxKSzVyPUGuO|M2QDZizszN NV3PRoUxW0GQR1XS
NCI-H747 M33QdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK3Z3R6UUN3ME2xMlc2OzR4IN88US=> M3zjV3NCVkeHUh?=
LU-165 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKyPHZKSzVyPUGuPFQ6QDZizszN NUjTOm9sW0GQR1XS
OMC-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm2bm1KSzVyPUGuPVUxPjZizszN NHzwVYVUSU6JRWK=
RCC10RGB NVHOOIpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP3TWM2OD1zLkm1PFE4KM7:TR?= MoDhV2FPT0WU
SW684 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq5S21KSzVyPUGuPVYxQTlizszN M{jKOXNCVkeHUh?=
TE-8 NFf0bWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\6VphzUUN3ME2yMlA2PTV7IN88US=> NYrIN4RHW0GQR1XS
SK-N-DZ NFywVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELOS3lKSzVyPUKuNVMzPzRizszN M{HH[XNCVkeHUh?=
EVSA-T MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzZVmluUUN3ME2yMlE4OzF3IN88US=> NED1eHJUSU6JRWK=
KASUMI-1 M4HJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7ETWM2OD1{LkG4PFE2KM7:TR?= NYm2eWhzW0GQR1XS
NKM-1 M4nkU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTVTWM2OD1{LkK1OFczKM7:TR?= M4DBbHNCVkeHUh?=
CAL-148 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojMTWM2OD1{LkOzOlE1KM7:TR?= NVnlfG9XW0GQR1XS
NCI-H64 NWTrO3FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL6TWM2OD1{LkO0NlMzKM7:TR?= MmHPV2FPT0WU
KNS-81-FD M3jzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXToe5h7UUN3ME2yMlM3PjJizszN NEixVm9USU6JRWK=
KM12 NWGwc2VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLjVZlQUUN3ME2yMlQxQDN7IN88US=> M1rjUnNCVkeHUh?=
SW954 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJwNEe3O|kh|ryP NXXoUZlTW0GQR1XS
NCI-H1395 NWf0WWhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJwNUK2OFUh|ryP MlvuV2FPT0WU
DJM-1 M1qxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;tRWlEPTB;Mj62NFY{KM7:TR?= MU\TRW5ITVJ?
COLO-668 NVzvV3NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r5cGlEPTB;Mj64NlY6PSEQvF2= M3W3ZXNCVkeHUh?=
NCI-H1436 MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvCTWM2OD1{Lki1OlE2KM7:TR?= MYjTRW5ITVJ?
LB2241-RCC Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rufWlEPTB;Mj64Olg{QSEQvF2= MmDoV2FPT0WU
GT3TKB NIfMcYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX0TWM2OD1{Lki5NFU2KM7:TR?= NVrQc|FVW0GQR1XS
COLO-824 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLkR5FKSzVyPUKuPFk4PjhizszN MXTTRW5ITVJ?
ES1 NFTTRoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DNSWlEPTB;Mj64PVg4QSEQvF2= MlzyV2FPT0WU
LB771-HNC NIXXeZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJwOUC5OFYh|ryP MmjKV2FPT0WU
GI-ME-N MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTNwMEC5NFQh|ryP MoW4V2FPT0WU
NALM-6 NFG5eYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvVTlFKSzVyPUOuNFA6OzNizszN MlvnV2FPT0WU
LU-134-A MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jFR2lEPTB;Mz6wOVQzPSEQvF2= NWDqVIVlW0GQR1XS
DMS-153 M{DTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTDW41[UUN3ME2zMlA2QDJ2IN88US=> MXnTRW5ITVJ?
MZ1-PC NVPOcmpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTNwMEmwO|gh|ryP MXHTRW5ITVJ?
NCI-H1155 Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\FVlBKSzVyPUOuNVE3OSEQvF2= NVriWJgxW0GQR1XS
CAS-1 MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTNwMUO3NFch|ryP NH3qcIVUSU6JRWK=
D-502MG NUftV3AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjTT2ZKSzVyPUOuNVQ{QSEQvF2= M2PnRnNCVkeHUh?=
NCI-H2141 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjjRXZKSzVyPUOuNVc1PTJizszN MV\TRW5ITVJ?
NB6 NITLcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXtTWM2OD1|LkG4NlU6KM7:TR?= NXTzRllSW0GQR1XS
NCCIT MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Ln[WlEPTB;Mz6yNVgxQSEQvF2= M4HTNnNCVkeHUh?=
NB69 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M171W2lEPTB;Mz6zNVg6OSEQvF2= NYfZcI5bW0GQR1XS
JVM-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTNwM{[0N|Mh|ryP NHfjcVRUSU6JRWK=
K052 NFjYXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTNwM{e5Olgh|ryP MVLTRW5ITVJ?
HCC2157 NVXmcIJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W2NGlEPTB;Mz61N|IzQCEQvF2= NETEdJNUSU6JRWK=
KMOE-2 NXrVeXNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTNwNUSyOFIh|ryP NFex[Y1USU6JRWK=
SF268 M3vkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnxeJZKSzVyPUOuO|E2PTRizszN MUHTRW5ITVJ?
CHP-126 NH7Xd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\iO49KSzVyPUOuO|Y1PThizszN MU\TRW5ITVJ?
CP66-MEL MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTNwN{mwPVQh|ryP MX;TRW5ITVJ?
NCI-H69 M1zoRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi3S|ZKSzVyPUSuNFE6OzZizszN MVXTRW5ITVJ?
A253 M4XRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1faN2lEPTB;ND6wNlExOSEQvF2= MljsV2FPT0WU
NB14 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLzTWM2OD12LkGwOFc6KM7:TR?= M4XHeXNCVkeHUh?=
NCI-H1694 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTRwMUOxNVIh|ryP NVK1UnR6W0GQR1XS
NCI-H2196 MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jze2lEPTB;ND6xO|E3QSEQvF2= MoHjV2FPT0WU
TE-9 MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF71[GdKSzVyPUSuNVc2QDJizszN NWjCOJpTW0GQR1XS
D-283MED MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTRwMUi4OEDPxE1? M4P0eXNCVkeHUh?=
OCI-AML2 Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXTTWM2OD12LkG5OFg6KM7:TR?= NHXYb|ZUSU6JRWK=
D-263MG NHzqNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTXc2JWUUN3ME20MlIzQTZzIN88US=> M3vEXnNCVkeHUh?=
MPP-89 M3nhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Lre2lEPTB;ND6yO|MxPCEQvF2= MkKzV2FPT0WU
LAMA-84 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DRe2lEPTB;ND6zNFQzOSEQvF2= NUTwcFc3W0GQR1XS
LB373-MEL-D NFnJcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLjTWM2OD12LkO2O|g6KM7:TR?= MnfNV2FPT0WU
UACC-257 M3LScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTRwM{m1N|Qh|ryP Mki5V2FPT0WU
MC-CAR NYLiZnVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXy2V|F7UUN3ME20MlQ{QTlizszN Mkn3V2FPT0WU
COLO-320-HSR MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3nTWM2OD12LkS0OFI4KM7:TR?= MVfTRW5ITVJ?
P30-OHK NGfid3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP6UFNKSzVyPUSuOlY2QDFizszN NV3RO2ZQW0GQR1XS
UACC-812 NInoWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLFTWM2OD12Lk[5NVYyKM7:TR?= MWDTRW5ITVJ?
CTB-1 MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTRwN{G1OVUh|ryP MoDRV2FPT0WU
ALL-PO NYOzdWl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjDdlJWUUN3ME20Mlg1ODd5IN88US=> NYH6U4FmW0GQR1XS
SK-MEL-2 NELxN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37zbWlEPTB;ND64Olk2PSEQvF2= NImwSnVUSU6JRWK=
TC-YIK NWXY[Y1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTRwOUe5OFIh|ryP NWnRcpJuW0GQR1XS
NCI-H1882 Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17OcmlEPTB;NT6wNlAxOSEQvF2= MlrmV2FPT0WU
MHH-CALL-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXsTWM2OD13LkC1NFQzKM7:TR?= MmX0V2FPT0WU
U-87-MG M1LIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTVwMEm0OlYh|ryP Mlz3V2FPT0WU
NCI-H1092 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[2Wpo2UUN3ME21MlI3PTV3IN88US=> NULrTHR2W0GQR1XS
TE-441-T MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnR[pk3UUN3ME21MlI4QDJizszN M1nQc3NCVkeHUh?=
SK-MEL-1 NIPnd4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLHbZdKSzVyPUWuNlkxPDRizszN MnX5V2FPT0WU
EW-22 Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfSbY1KSzVyPUWuNlk1PjZizszN NIj4SY5USU6JRWK=
MZ7-mel NX7sPZVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTVwNEC2PVEh|ryP M2jJ[nNCVkeHUh?=
LP-1 M{\YVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLoZmlKSzVyPUWuOFEzQTFizszN MVHTRW5ITVJ?
NCI-SNU-16 M2L1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWizSI9pUUN3ME21MlY1ODd2IN88US=> NYO0Om1qW0GQR1XS
LU-65 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH5TWM2OD13Lke2N|c{KM7:TR?= MUfTRW5ITVJ?
CW-2 NELXRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDpTWM2OD13Lki1PVU6KM7:TR?= NF:xSohUSU6JRWK=
WSU-NHL M1O4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvpdnlKSzVyPUWuPVUyPzRizszN MYnTRW5ITVJ?
IST-MES1 NVLTSZZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTVwOUW0OFMh|ryP MXHTRW5ITVJ?
U-266 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTVwOUiyNFIh|ryP NGH3U5RUSU6JRWK=
TALL-1 MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HCdmlEPTB;Nj6xOFY5QCEQvF2= NVezSpU{W0GQR1XS
Calu-6 NGXXNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonKTWM2OD14LkG1N|E3KM7:TR?= NXz5V|R[W0GQR1XS
MMAC-SF NUjicGFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3i0fWlEPTB;Nj6xPFU2PiEQvF2= NULZVHpuW0GQR1XS
NCI-H82 NWfoNIdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\hSpNTUUN3ME22MlIxPDh7IN88US=> MmXEV2FPT0WU
RS4-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTEOYo1UUN3ME22MlI2QDl5IN88US=> M1\2[XNCVkeHUh?=
SNU-C2B NWDhVJI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTZwNEC5Olkh|ryP NULKTFRXW0GQR1XS
BOKU M4\RdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYThUYFoUUN3ME22MlQ4PTl5IN88US=> NYq1fHF1W0GQR1XS
C8166 NYq0SlZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\Ye2loUUN3ME22MlU2QTF{IN88US=> NHHqe4tUSU6JRWK=
D-247MG Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTdwMESzOFch|ryP MUDTRW5ITVJ?
EW-18 NXTYfmJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPz[VdKSzVyPUeuNFczQTJizszN NH7oO4dUSU6JRWK=
KG-1 NXXiN4NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTnS3hKSzVyPUeuOlI4OzhizszN M3HEOnNCVkeHUh?=
REH NW\RPVkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly0TWM2OD15Lk[4NVA6KM7:TR?= NGrxfohUSU6JRWK=
U-698-M M3Hldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLWcYp{UUN3ME23Mlg1OzF3IN88US=> NYTXTVVjW0GQR1XS
KP-N-RT-BM-1 M3z1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTdwOUOwNlkh|ryP M3\X[XNCVkeHUh?=
MS-1 NVXJN2w{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPIeItkUUN3ME23Mlk3ODRzIN88US=> M{nZbHNCVkeHUh?=
SNU-C1 Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjOTWM2OD15Lkm4NVkzKM7:TR?= M3HqXnNCVkeHUh?=
SK-MM-2 MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvsTWM2OD16LkK2NFY2KM7:TR?= NGq5SnRUSU6JRWK=
LAN-6 NIfoe|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2OxemlEPTB;OD6zNFAxOSEQvF2= M3zVOnNCVkeHUh?=
NEC8 NXfkTm54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSzTWM2OD16LkOwOlkyKM7:TR?= MW\TRW5ITVJ?
NCI-H1770 M4\t[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHYTI1KUUN3ME24MlM5ODB{IN88US=> NFuwbnlUSU6JRWK=
D-336MG MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRThwNECxNVYh|ryP NEPmOldUSU6JRWK=
COLO-829 M1G3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofpTWM2OD16LkS4PFc6KM7:TR?= MliyV2FPT0WU
LS-513 MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTzd3g3UUN3ME24MlU6PTl7IN88US=> M4LKUXNCVkeHUh?=
YT NW\6c2VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOzTWM2OD16Lk[yOFI4KM7:TR?= NGTv[2xUSU6JRWK=
EW-24 NF[5d5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRThwN{[1OEDPxE1? MVrTRW5ITVJ?
IST-SL1 M2f3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRThwOE[1OFMh|ryP MonxV2FPT0WU
CA46 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnZ[VJKSzVyPUiuPVUxQThizszN MXvTRW5ITVJ?
NCI-H1838 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu2TWM2OD16Lkm4OlAzKM7:TR?= M{ToRnNCVkeHUh?=
NCI-H719 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW3TWM2OD17LkK1Nlc6KM7:TR?= NYTzPXNiW0GQR1XS
HCE-T NH7TcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzqTWM2OD17LkOwPFUyKM7:TR?= NHX6eZZUSU6JRWK=
A498 MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTlwM{[xNlQh|ryP MmqyV2FPT0WU
LB831-BLC M33tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn2eXNSUUN3ME25Mlc3PTJzIN88US=> MmfBV2FPT0WU
SKM-1 M17tXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\XTWM2OD17Lki1PVY{KM7:TR?= MmntV2FPT0WU
THP-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jCOmlEPTB;OT65OlkyQCEQvF2= MXzTRW5ITVJ?
SHP-77 MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlG2TWM2OD1zMD60NFch|ryP NH;6doZUSU6JRWK=
EW-3 M3:y[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFyLk[yPFkh|ryP MUjTRW5ITVJ?
KY821 NUK2ZpdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrKTWM2OD1zMD63OlMh|ryP M4nKb3NCVkeHUh?=
NCI-SNU-1 NYHHd|hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPXTWM2OD1zMT6wNlE4KM7:TR?= MWXTRW5ITVJ?
HCC2218 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;WRWlEPTB;MUGuN|k5PiEQvF2= MVjTRW5ITVJ?
IM-9 NU[1WolxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfP[VNKSzVyPUGxMlUyODZizszN NUHK[W45W0GQR1XS
NCI-H889 NVLp[Jo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DkTGlEPTB;MUGuOVMyOyEQvF2= M3u4OHNCVkeHUh?=
HDLM-2 NGLJeoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnEVWdKSzVyPUGyMlQyPTlizszN MWLTRW5ITVJ?
LB2518-MEL Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\GNGxmUUN3ME2xNk43QDF3IN88US=> MkT5V2FPT0WU
NCI-H23 M1LoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M361XGlEPTB;MUOuNlQzPSEQvF2= M17vTnNCVkeHUh?=
NB17 MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTF|LkS1O|kh|ryP M4LOVHNCVkeHUh?=
NCI-H322M NEfIWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr1TWM2OD1zND60NFY5KM7:TR?= NF3xWGJUSU6JRWK=
SUP-T1 NVPDeZdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj4fnQ5UUN3ME2xOE41OTNizszN NG\vR5VUSU6JRWK=
ES3 NH;LXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF3LkC3NFMh|ryP M4DvTHNCVkeHUh?=
ES5 M1fxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T2W2lEPTB;MUWuNFc5PyEQvF2= MVfTRW5ITVJ?
NCI-H1650 MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF3LkS5O|kh|ryP MnPhV2FPT0WU
NCI-H226 NXrPR2R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;ue2lEPTB;MUWuPFc3QCEQvF2= MoD6V2FPT0WU
COR-L88 Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTlW4VuUUN3ME2xOk4{OTRizszN MlnLV2FPT0WU
SCC-15 NVq5R3hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ewSWlEPTB;MU[uN|g3QSEQvF2= NEjOXY1USU6JRWK=
GOTO MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;1eGlEPTB;MU[uOFc6OyEQvF2= NGfpOndUSU6JRWK=
SIMA MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LlUmlEPTB;MU[uOFgxOiEQvF2= NXTGe2ZTW0GQR1XS
NCI-H1299 NIrrXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnzRno4UUN3ME2xO{4yPTlzIN88US=> NIrWXndUSU6JRWK=
NCI-H1581 M3\mV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j6SWlEPTB;MUeuOFIyQSEQvF2= NWL0e2l6W0GQR1XS
MHH-NB-11 M{fVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLVTWM2OD1zNz65Olg{KM7:TR?= MkTGV2FPT0WU
MFM-223 MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPxN2x[UUN3ME2xPE4xPTN6IN88US=> NYPwfJpZW0GQR1XS
ES7 MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3XTWM2OD1zOD61OFMyKM7:TR?= NXPmdmg6W0GQR1XS
JVM-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTF6LkexO{DPxE1? M3XkUHNCVkeHUh?=
RL NEDJT5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJyLkO4PEDPxE1? NG\LemJUSU6JRWK=
EC-GI-10 NIi0bIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHnTWM2OD1{MT6yNFQyKM7:TR?= MUXTRW5ITVJ?
LNCaP-Clone-FGC NHnt[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L0cGlEPTB;MkGuOlc3QCEQvF2= Mn3FV2FPT0WU
IMR-5 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDnXGhKSzVyPUKxMlg1QTRizszN MUXTRW5ITVJ?
KP-N-YS M3PYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJzLki3OUDPxE1? MYXTRW5ITVJ?
Mo-T M1;6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPwTWM2OD1{Mj6yNVg2KM7:TR?= NE[2U3FUSU6JRWK=
NCI-H128 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\GUmlEPTB;MkOuOVg2OyEQvF2= M3vk[XNCVkeHUh?=
RH-1 NILScHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfwTJdKUUN3ME2yN{44QDZ4IN88US=> M2O3SnNCVkeHUh?=
NCI-H2171 M4TRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrFeJpbUUN3ME2yOE4zPDh3IN88US=> M{PKUHNCVkeHUh?=
RPMI-8866 NITkXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzOV4pKSzVyPUK2Mlc1OiEQvF2= M1X5cHNCVkeHUh?=
SK-N-FI M{TLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJ5LkO4NVEh|ryP MX3TRW5ITVJ?
LOXIMVI M{Dl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDpTWM2OD1{Nz64NFUyKM7:TR?= NUXQW5hTW0GQR1XS
P31-FUJ MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjHSJBKSzVyPUOxMlU{PzRizszN NVvnbnRUW0GQR1XS
KMS-12-PE NEfPfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rFO2lEPTB;NEmuOVMxOiEQvF2= NH7RO4NUSU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 在体内,Rapamycin 处理,特定阻断mTOR下游靶点,如p70S6K磷酸化和激活,和PHAS-1/4E-BP1导致的eIF4E抑制释放, 完全阻断跖肌重量和纤维尺寸的肥厚增高。[3] 短期Rapamycin处理,即使按最低剂量0.16 mg/kg处理, 强抑制p70S6K活性, 与提高的肿瘤细胞死亡和Eker肾脏肿瘤坏死相关。[4] Rapamycin作用于CT-26移植瘤模型,通过降低VEGF产量,及阻断VEGF诱导的内皮细胞信号,而抑制转移性肿瘤生长和血管新生。[5] Rapamycin每天按4 mg/kg剂量处理C6移植瘤,显著降低肿瘤生长,和肿瘤血管通透性。[7]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

mTOR激酶免疫印迹法测定:

HEK293细胞按每孔2-2.5×105个细胞接种在12孔板上,DMEM培养基上血清饥饿处理24小时。使用浓度不断增加的Rapamycin(0.05-50 nM)在 37oC下处理细胞15分钟。加入血清,终浓度为20%,在37oC下处理30分钟。细胞溶解,使用SDS-PAGE分离细胞裂解液。再溶解的蛋白转移到聚偏(二)氟乙烯膜上,使用抗p70 S6激酶Thr-389的磷酸化的一抗进行免疫印迹。使用ImageQuant 和KaleidaGraph分析数据。
细胞实验:

[6]

+ 展开
  • Cell lines: U87-MG, T98G, 和 U373-MG
  • Concentrations: 溶于DMSO,终浓度为~25 μM
  • Incubation Time: 72 小时
  • Method:

    使用不同浓度Rapamycin处理细胞72小时。为了测量细胞活力,通过胰蛋白酶化收集细胞,使用台酚蓝染色,计数每孔的存活细胞数。为了测定细胞周期, 使细胞胰蛋白酶化,与70%乙醇混合, 使用碘化丙啶染色。使用FACScan流式细胞仪和CellQuest软件分析样本DNA含量。为了测定凋亡, 细胞染色,通过末端脱氧核苷酸转移酶调节的dUTP缺口末端标记法(TUNEL)技术,使用一个ApopTag凋亡检测试剂盒对细胞进行染色。为了测定酸性囊泡细胞器(AVO)的进展,使用吖啶橙(1 μg/mL)对细胞进行染色15分钟,使用荧光显微镜检测。为了量化AVOs的进展,使用吖啶橙(1 μg/mL) 对细胞进行染色15分钟, 然后使用胰蛋白酶-EDTA使其从实验板上移除,最后使用FACScan流式细胞仪和CellQuest 软件分析。为了分析自噬过程,细胞和0.05 mM丹(磺)酰戊二胺(MDC)在37oC下温育10分钟,然后在荧光显微镜下观察。


    (Only for Reference)
动物实验:

[7]

+ 展开
  • Animal Models: 皮下接种表达VEGF-A的C6大鼠胶质瘤细胞的无胸腺Nu/Nu小鼠
  • Formulation: 溶于溶剂溶液(0.2% 羧甲基纤维素和0.25% Tween-80,溶于无菌水)
  • Dosages: ~4 mg/kg/day
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 914.18
化学式

C51H79NO13

CAS号 53123-88-9
稳定性 powder
in solvent
别名 AY 22989,NSC-2260804

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03454724 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. April 1 2019 Not Applicable
NCT03531281 Not yet recruiting Hematopoietic and Lymphoid Cell Neoplasm|Hematopoietic Cell Transplantation Recipient City of Hope Medical Center|National Cancer Institute (NCI) December 30 2018 Phase 1
NCT03298958 Not yet recruiting Bladder Cancer The University of Texas Health Science Center at San Antonio December 1 2018 Phase 3
NCT03433183 Not yet recruiting Malignant Peripheral Nerve Sheath Tumors|Neurofibromatosis 1 Sarcoma Alliance for Research through Collaboration|United States Department of Defense|AstraZeneca December 2018 Phase 2
NCT03721614 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. December 1 2018 Not Applicable
NCT03203525 Not yet recruiting Liver Cancer M.D. Anderson Cancer Center|NovoCure Ltd. December 2018 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

相关mTOR产品

Tags: 购买Rapamycin (Sirolimus) | Rapamycin (Sirolimus)供应商 | 采购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)价格 | Rapamycin (Sirolimus)生产 | 订购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID